Auris Medical Am 111

At Manningham Medical Centre, you can find all the data about Auris Medical Am 111. We have collected data about general practitioners, medical and surgical specialists, dental, pharmacy and more. Please see the links below for the information you need.

Altamira Therapeutics - Inner Ear …

https://www.aurismedical.com/programs/inner-ear-therapeutics

Development status. AM-125 for the treatment of vertigo is expected to complete its Phase 2 TRAVERS trial in Q2 2022 and to move into Phase 3 in Q4 2022. Keyzilen ® (AM …

Auris Medical Announces Publication of AM-111 Phase 3

https://www.globenewswire.com/news-release/2019/03/11/1751210/0/en/Auris-Medical-Announces-Publication-of-AM-111-Phase-3-Results-in-Peer-Reviewed-Scientific-Journal.html

AM-111's otoprotective effects have been demonstrated in various animal models of cochlear stress, including acute acoustic trauma, acute labyrinthitis (inflammation), drug …

Auris Medical Announces Publication of AM-111 Phase 3 …

https://www.nasdaq.com/press-release/auris-medical-announces-publication-am-111-phase-3-results-peer-reviewed-scientific

AM-111's otoprotective effects have been demonstrated in various animal models of cochlear stress, including acute acoustic trauma, acute labyrinthitis …

Altamira Therapeutics – Inner Ear Therapeutics - Auris …

https://www.aurismedical.com/science/inner-ear-therapeutics

How Sonsuvi ® (AM-111) works JNK is a signal transmitting enzyme that regulates several important cellular activities, including activation of genes encoding inflammatory …

Auris Announces FDA Fast Track Designation For AM-111

https://hearingreview.com/inside-hearing/industry-news/auris-announces-fda-fast-track-designation-111

Auris Medical Holding AG, a Swiss biopharmaceutical company dedicated to developing therapeutics to treat inner ear disorders, announced on February 24 that …

Auris Medical Provides Update on AM-111 Development

https://www.globenewswire.com/news-release/2018/01/04/1283360/0/en/Auris-Medical-Provides-Update-on-AM-111-Development-Program.html

AM-111 was well tolerated and the primary safety endpoint was met. AM-111 treated patients had a lower incidence of no hearing improvement Further analyses on …

Auris Medical

https://www.aurismedical.com/

Auris Medical is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in RNA therapeutics, allergy and viral infections, …

Auris Medical AM-111 | Tinnitus Talk Support Forum

https://www.tinnitustalk.com/threads/auris-medical-am-111.728/

Auris Medical announced today positive results from a phase IIb clinical trial with AM-111, its investigational drug for the intratympanic (i.t.) treatment of acute …

Auris Medical's Acute Inner Ear Hearing …

https://www.genengnews.com/news/auris-medicals-acute-inner-ear-hearing-loss-candidate-fails-phase-iii-trial/

AM-111 contains brimapitide, or D-JNKI-1 (D-stereoisomer of c-Jun N-terminal kinase inhibitor 1), an inhibitor of the JNK stress kinase coupled to an …

Efficacy and Safety of AM-111 as Acute Sudden …

https://clinicaltrials.gov/ct2/show/NCT02809118

Study Description. The primary objective of the trial is the confirmation of the efficacy of AM-111 in the recovery of severe to profound idiopathic sudden sensorineural …

Need more information about Auris Medical Am 111?

At Manningham Medical Centre, we collected data on more than just Auris Medical Am 111. There is a lot of other useful information. Visit the related pages or our most popular pages. Also check out our Doctors page.